Epirubicin, Hydrochloride Salt (Ellence, Epiadriamycin, 4'-Epidoxorubicin, IMI-28, Pharmorubicin, Ridorubicin, CAS 56390-09-1), >99%

LC Laboratories' Product Number E-8000 - Epirubicin, Hydrochloride Salt (Ellence, Epiadriamycin, 4'-Epidoxorubicin, IMI-28, Pharmorubicin, Ridorubicin, CAS 56390-09-1), >99% - for research use only. Epirubicin is an anthracycline drug used for cancer chemotherapy. Epirubicin-containing regimens are better than those containing cyclophosphamide, methotrexate and fluorouracil (CMF) for treatment of early breast cancer. "Polychemotherapy for early breast cancer: an overview of the randomised trials. The mechanisms of antitumor activity of anthracyclines may include 1) inhibition synthesis of macromolecules by intercalation into DNA; 2) DNA damage or lipid peroxidation by generation of free radicals; 3) DNA cross-linking; 4) DNA binding and alkylation; 5) interference with DNA unwinding, DNA strand separation, and helicase activity; 6) membrane effects; and 7) initiation of DNA damage by inhibition of topoisomerase II, and thus induction of apoptosis. Several clinical trials have demonstrated that epirubicin-containing regimens at equimolar doses achieved equivalent objective response rates and overall median survival as doxorubicin-containing regimens in the treatment of advanced and early breast cancer, non-small cell lung cancer and small cell lung cancer, non-Hodgkin's lymphoma, gastric cancer, ovarian cancer and nonresectable primary hepatocellular carcinoma. Epirubicin and doxorubicin are two major anthracyclines. At equimolar doses, these two anthracyclines showed similar response rates. The major side effects of anthracyclines are cardiotoxicity and myelosuppression. Epirubicin, having less toxicity at similar doses, represents an alternative to doxorubicin for breast cancer treatment. Epirubicin is the active ingredient in the drug product sold under the trade name Ellence® and other trade names. This drug is currently approved in at least one country for use in patients with breast cancer, and is used for treatment of various other cancers. NOTE: The Epirubicin, Hydrochloride Salt research compound sold by LC Laboratories is NOT Ellence® nor any other epirubicin drug product, and is NOT for human use. This epirubicin product is the hydrochloride salt, whose CAS number is given above. The CAS number of the free base is 56420-45-2.

• Supplier: LC Laboratories
• Product #: E-8000
• Sku #: E-8000_25mg